Liquidia Technologies

Yahoo Finance • 23 days ago

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will... Full story

Yahoo Finance • 23 days ago

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will... Full story

Yahoo Finance • 27 days ago

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and... Full story

Yahoo Finance • last month

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil products in clinical studiesStrengthened financial position by up to $100 million via amendment... Full story

Yahoo Finance • last month

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report it... Full story

Yahoo Finance • 2 months ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral d... Full story

Yahoo Finance • 8 months ago

Estee Lauder, Liquidia, B. Riley fall premarket; AMD rises

Investing.com -- U.S. stock futures traded largely unchanged Monday, consolidating after the previous week’s strong gains and ahead of the release this week of the minutes from the latest Federal Reserve meeting. Here are some of the bigg... Full story

Yahoo Finance • last year

16 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story

Yahoo Finance • last year

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024Hired sales force in preparation of potential positive legal and regulatory outcomes MORR... Full story

Yahoo Finance • 2 years ago

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring... Full story

Yahoo Finance • 2 years ago

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced tod... Full story

Yahoo Finance • 2 years ago

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Bo... Full story

Yahoo Finance • 2 years ago

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizerLiquidia funds $10 million upfront payment from finance agreement... Full story

Yahoo Finance • 2 years ago

Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference

MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation... Full story

Yahoo Finance • 2 years ago

Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)

PTAB rejects UTHR’s request for rehearing of its decision in the inter partes review of the ‘793 Patent (‘793 IPR)PTAB clarified grounds upon which it based its finding that the cited publications, which invalidated the claims, constituted... Full story

Yahoo Finance • 2 years ago

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia’s common stock to newly hired non-ex... Full story

Yahoo Finance • 2 years ago

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million

Extends cash-runway through at least 2024Provides flexibility to accelerate launch preparations timed with success in litigation MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the C... Full story

Yahoo Finance • 2 years ago

Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec.... Full story

Yahoo Finance • 2 years ago

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the third quarter ended September 30, 2022. The Company will host a webcast and c... Full story

Yahoo Finance • 2 years ago

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The company will host a conference call a... Full story